Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses

Thangavelu, G., C. Wang, M. Loschi, A. Saha, M. Osborn, S. N. Furlan, K. Aoyama, C. McDonald-Hyman, E. G. Aguilar, A. S. Janesick, R. A. Chandraratna, Y. Refaeli, A. Panoskaltsis-Mortari, K. P. MacDonald, G. R. Hill, R. Zeiser, I. Maillard, J. Serody, W. J. Murphy, D. H. Munn, B. Blumberg, C. Brown, V. K. Kuchroo, L. S. Kean, K. Hippen, R. J. Noelle, and B. R. Blazar. 2020. Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. Blood. 137(8):1090-1103. doi: 10.1182/blood.2020005628.

Categorised in:

This post was written by Heike Ufheil